Brief: Agenus' Botensilimab In Combination With Balstilimab Shows 33% Durable Responses In Ovarian Cancer
27/03/2023 14:52
March 27 (Reuters) - Agenus Inc AGEN.O :
* AGENUS’ BOTENSILIMAB IN COMBINATION WITH BALSTILIMAB SHOWS
33%
DURABLE RESPONSES IN OVARIAN CANCER
Source text for Eikon: ID:nBw2GShV1a
Further company coverage: AGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income